These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38387852)

  • 1. Negative impact of comorbidities on all-cause mortality of patients with psoriasis is partially alleviated by biologic treatment: A real-world case-control study.
    Riaz S; Emam S; Wang T; Gniadecki R
    J Am Acad Dermatol; 2024 Jul; 91(1):43-50. PubMed ID: 38387852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
    Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
    J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study.
    Kridin K; Schonmann Y; Tzur Bitan D; Damiani G; Peretz A; Weinstein O; Cohen AD
    Am J Clin Dermatol; 2021 Sep; 22(5):709-718. PubMed ID: 34060006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
    Feldman SR; Zhao Y; Shi L; Tran MH
    J Manag Care Spec Pharm; 2015 Oct; 21(10):874-88. PubMed ID: 26402388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis.
    Langley RG; Poulin Y; Srivastava B; Lafferty KP; Fakharzadeh S; Langholff W; Augustin M
    J Am Acad Dermatol; 2021 Jan; 84(1):60-69. PubMed ID: 32798580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
    Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
    J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Biologics Protect Patients With Psoriasis From Myocardial Infarction? A Retrospective Cohort.
    Gulliver WP; Randell S; Gulliver S; Connors S; Bachelez H; MacDonald D; Gladney N; Morrissey A; Fleming P
    J Cutan Med Surg; 2016 Nov; 20(6):536-541. PubMed ID: 27207347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruña, Spain.
    Fernández-Torres RM; Pita-Fernández S; Fonseca E
    Int J Dermatol; 2014 Nov; 53(11):e507-11. PubMed ID: 25266080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis Patients Treated With Biologics and Methotrexate Have a Reduced Rate of Myocardial Infarction: A Collaborative Analysis Using International Cohorts.
    Gulliver WP; Young HM; Bachelez H; Randell S; Gulliver S; Al-Mutairi N
    J Cutan Med Surg; 2016 Nov; 20(6):550-554. PubMed ID: 27402717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
    Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
    J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study.
    Margolis DJ; Shin D; Noe MH; Wan MT; Bhate K; Wang S; Hoffstad O; Takeshita J; Gelfand JM
    J Am Acad Dermatol; 2019 Sep; 81(3):709-716. PubMed ID: 31054973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.
    Carretero Hernández G; Ferrándiz C; Rivera Díaz R; Daudén Tello E; de la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Belinchón Romero I; López-Estebaranz JL; Alsina Gibert M; Sánchez-Carazo JL; Ferrán Farrés M; González Quesada A; Carrascosa Carrillo JM; Llamas-Velasco M; Mendiola Fernández MV; Ruiz Genao D; Muñoz Santos C; García-Doval I; Descalzo MA;
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):617-623. PubMed ID: 29887167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
    Kamata M; Tada Y
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32121574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.
    Edson-Heredia E; Anderson S; Guo J; Zhu B; Malatestinic WN; Wine-Lee L; Swanson E
    Adv Ther; 2021 Jul; 38(7):3948-3961. PubMed ID: 34091866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
    Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Dermatolog Treat; 2022 Nov; 33(7):2975-2982. PubMed ID: 35737885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.